Inhibrx Biosciences, Inc. reports clinical and corporate updates for a pipeline of biologic therapeutic candidates developed with protein engineering platforms. The company’s programs include ozekibart (INBRX-109), a tetravalent death receptor 5 agonist antibody studied in oncology indications including chondrosarcoma, colorectal cancer and Ewing sarcoma, and INBRX-106, a hexavalent OX40 agonist evaluated in immuno-oncology settings such as head and neck squamous cell carcinoma.
Company developments commonly cover clinical trial data, regulatory submissions and designations, scientific conference presentations, quarterly and annual financial results, and capital resources. Inhibrx Biosciences also carries a completed corporate history tied to its 2024 separation from Inhibrx, Inc. following the sale of the INBRX-101 program.
Inhibrx, a clinical-stage biotechnology company, has successfully completed its initial public offering (IPO) of 8,050,000 shares, including an over-allotment of 1,050,000 shares, priced at $17.00 per share. This IPO generated approximately $136.9 million in gross proceeds. The stock began trading on the Nasdaq under the symbol INBX on August 19, 2020. Jefferies, Evercore ISI, and Credit Suisse were the joint book-running managers for the offering, with LifeSci Capital serving as co-manager. The prospectus for this offering is available from the managing firms.